H Carl LeKaye

Dr. H Carl LeKaye


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2009 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
HLH Carl LeKaye
H Carl LeKaye
MLMihaela Lupu
Mihaela Lupu
KKKhushali Kotedia
Khushali Kotedia
NRNeal Rosen
Neal Rosen
DSDavid Solit
David Solit
JKJason A. Koutcher
Jason A. Koutcher

15 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RPRamesh Paudyal
Ramesh Paudyal
JRJames Russell
James Russell
HLH Carl LeKaye
H Carl LeKaye
JDJoseph O. Deasy
Joseph O. Deasy
JHJohn L. Humm
John L. Humm
ASAmita Shukla-Dave
Amita Shukla-Dave
Background/Objectives: The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by an enriched stroma, hampering the effectiveness of therapy. This co-clinical study aimed to (1) provide insight into early post-treatment changes in the TME using multiparametric magnetic resonance imaging (mpMRI)-derived quantitative imaging biomarkers (QIBs) in a preclinical PDAC model treated with radiotherapy and correlate these QIBs with histology; (2) evaluate the feasibility of obtaining these QIBs in patients with PDAC using clinically approved mpMRI data acquisitions. Methods: Athymic mice (n = 12) at pre- and post-treatment as well as patients with PDAC (n = 11) at pre-treatment underwent mpMRI including diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) data acquisition sequences. DW and DCE data were analyzed using monoexponential and extended Tofts models, respectively. DeepLIIF quantified the total percentage (%) of tumor cells in hematoxylin and eosin (H&E)-stained tissues from athymic mice. Spearman correlation and Wilcoxon signed rank tests were performed for statistical analysis. Results: In the preclinical PDAC model, mean pre- and post-treatment ADC and Ktrans values differed significantly (p < 0.01), changing by 20.50% and 20.41%, respectively, and the median total tumor cells quantified by DeepLIIF was 24% (range: 15–53%). Post-treatment ADC values and relative change in ve (rΔve) showed a significant negative correlation with total tumor cells (ρ = −0.77, p < 0.014 for ADC and ρ = −0.77, p = 0.009 for rΔve). In patients with PDAC, pre-treatment mean ADC and Ktrans values were 1.76 × 10−3 (mm2/s) and 0.24 (min−1), respectively. Conclusions: QIBs in both preclinical and clinical settings underscore their potential for future co-clinical research to evaluate emerging drug combinations targeting both tumor and stroma.